Merck announced the U.S. Food and Drug Administration (FDA) approved supplemental New Drug Applications (sNDAs) for PIFELTRO™ (in combination with other antiretroviral agents) and DELSTRIGO™ (as a complete regimen) that expand their indications to include adult patients with HIV-1 infection who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to PIFELTRO or the individual components of DELSTRIGO.
PIFELTRO (doravirine, 100 mg) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) to be administered in combination with other antiretroviral agents. DELSTRIGO is a once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg). DELSTRIGO contains a boxed warning regarding post-treatment acute exacerbation of hepatitis B virus (HBV) infection. DELSTRIGO and PIFELTRO do not cure HIV-1 infection or AIDS. PIFELTRO and DELSTRIGO were approved in the United States on August 30, 2018 for the treatment of HIV-1 infection in adults with no prior antiretroviral treatment history.
PIFELTRO and DELSTRIGO are contraindicated when co-administered with drugs that are strong cytochrome P450 (CYP)3A enzyme inducers as significant decreases in doravirine plasma concentrations may occur, which may decrease the effectiveness of PIFELTRO and DELSTRIGO (doravirine/lamivudine (3TC)/tenofovir disoproxil fumarate (TDF)). DELSTRIGO is contraindicated in patients with a previous hypersensitivity reaction to 3TC. For more information, please see "Selected Safety Information" below.
"Thanks to developments in HIV science, more treatment options are becoming available to address the medical needs of people living with HIV," said Dr. Princy Kumar, Chief, Division of Infectious Diseases and Tropical Medicine at MedStar Georgetown University Hospital and Professor of Medicine and Microbiology, Georgetown University School of Medicine, Washington, D.C. "The expanded indications offer certain people with HIV-1 infection, and their doctors, the choice to switch their current antiretroviral therapy to DELSTRIGO or PIFELTRO in combination with other antiretroviral agents."
Immune reconstitution syndrome can occur in patients treated with combination antiretroviral therapy, including the occurrence of autoimmune disorders with variable time to onset, which may necessitate further evaluation and treatment. Renal impairment, including cases of acute renal failure and Fanconi syndrome, have been reported with the use of TDF. DELSTRIGO should be avoided with concurrent or recent use of a nephrotoxic agent, as cases of acute renal failure after initiation of high-dose or multiple non-steroidal anti-inflammatory drugs (NSAIDs) have been reported in patients with risk factors for renal dysfunction who appeared stable on TDF.
The FDA’s approval of the sNDAs of PIFELTRO and DELSTRIGO was based on findings from DRIVE-SHIFT, the Phase 3 randomized, international, multicenter, open-label trial evaluating a switch to DELSTRIGO in virologically suppressed participants (HIV-1 RNA <50 copies/mL) on a baseline regimen for at least six months prior to trial entry with no history of virologic failure. The baseline regimen consisted of two nucleoside reverse transcriptase inhibitors (NRTIs) in combination with a protease inhibitor plus either ritonavir or cobicistat, or elvitegravir plus cobicistat, or an NNRTI.
In DRIVE-SHIFT, 670 participants were randomized to begin treatment with DELSTRIGO immediately on Day 1 (immediate switch group, ISG; N=447) or after 24 weeks (delayed switch group, DSG; N=223). In the trial, the primary efficacy comparison was between the DELSTRIGO ISG at Week 48 and the baseline regimen DSG at Week 24. Two percent in the DELSTRIGO ISG had HIV-1 RNA ≥50 copies/mL at Week 48 compared to 1% in the baseline regimen DSG at Week 24 (treatment difference: 0.7%, 95% confidence interval: -1.3, 2.6). In add...
(All Rights Reserved)